8 min
New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376 Frankly Speaking About Family Medicine
-
- Science
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376
Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.
Episode resource links:
DM/HF: Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254
Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660
Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376
Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.
Episode resource links:
DM/HF: Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254
Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660
Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato
8 min